✨ Free AI Report
Cellectis S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Cellectis S.A.
Research Preview

Cellectis S.A.: Business Overview, Financials & Competitive Analysis

Cellectis is a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies. The company utilizes its proprietary TALEN (Transcription Activator-Like E...

Analyst-debate audio for Cellectis S.A.

AskCyborg analysts argue the bull and bear cases for Cellectis S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cellectis S.A. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
6/ 10Solid

Cyborg Score thesis

Cellectis is a late-stage CAR-T immunotherapy player with differentiated allogeneic platform and pivotal trial catalysts that...

Read the full analyst-debate transcript →
Industry Gene Therapy
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 26, 2026
AI-Generated Research
30+ Page Report

Get the Latest Cellectis S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Cellectis S.A. Overview

Pro stress-test →

Cellectis is a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies. The company utilizes its proprietary TALEN (Transcription Activator-Like Effector Nucleases) technology to engineer innovative cell therapies and aims to harness the power of the immune system to identify and destroy cancer cells more effectively.

Strategic Profile

Pro stress-test →

Cellectis transitioned in 2025 to a late-stage development allogeneic CAR-T company with the initiation of a pivotal Phase 2 trial for lasme-cel. Lasme-cel demonstrated a potentially transformative efficacy profile in one of oncology's most challenging settings, achieving 100% overall response rate in the target Phase 2 population, critically converting all patients in the target population into transplant-eligible candidates.

Competitive Landscape

Pro stress-test →

Cellectis competes in the allogeneic CAR-T immunotherapy space against companies like Allogene Therapeutics (cema-cel/UCART19 partnership history), Juno Therapeutics, and other CAR-T developers. Key differentiation is the TALEN gene-editing platform enabling off-the-shelf cell therapies. Strategic partnership with AstraZeneca provides collaboration revenue and development support.

Industry Context

Cellectis S.A. operates in Gene Therapy.

Key facts

Founded: 2007 · Headquarters: Paris, France · Employees: N/A · Revenue: $7.5M (Q1 2026) · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Cellectis S.A..

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Cellectis S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

TecartusAutologous CAR-T cell immunotherapy for mantle cell lymphoma→Allogene TherapeuticsAllogeneic CAR-T cell therapy developer→KymriahApproved CAR-T immunotherapy for acute lymphoblastic leukemia→

Compare Cellectis S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cellectis S.A. operates in Gene Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Gene Therapy research →
NEW · MCP server

Ask your AI assistant about Cellectis S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cellectis S.A. and its top competitor on Cyborg Score”
“What did Cellectis S.A. do this quarter?”
“Is Cellectis S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Cellectis S.A. do?+
Cellectis is a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies. The company utilizes its proprietary TALEN (Transcription Activator-Like E...
What is Cellectis S.A.'s Cyborg Score?+
Cellectis S.A. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cellectis S.A.'s main competitors?+
Named competitors include Tecartus, Allogene Therapeutics, Kymriah. The full competitive landscape is in the AskCyborg report.
How can I get the full Cellectis S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cellectis S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cellectis S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Gene Therapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4uniQure N.V.